Becker's Healthcare September 19, 2024
Alexandra Murphy

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.

The company plans to offer 7.5 million shares priced between $17 and $19 each,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
AbbVie to write off $3.5B over failed schizophrenia drug
Drug Price Negotiation Requires Oversight To Protect Older Americans
5 questions facing emerging biotech in 2025
Lantheus (LNTH) Acquires Life Molecular Imaging for $750M
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too

Share This Article